Perspectum Stock

perspectum.comHealthcareFounded: 2012

Perspectum is a biotech firm serving healthcare providers with imaging services to help them make diagnostics and treatment decisions for their patients. Perspectum’s imaging technology is patented and contains a one scan approach able to produce a three-dimensional return. The private company’s devices are fully integrated into any healthcare setting and can be used by physicians, imaging providers, and pharma solutions to provide full treatment of ailments such as liver disease, diabetes, and cancer.

Register for Details

For more details on financing and valuation for Perspectum, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

Enterprise Value (based on primary financings)

Powered by Forge Data
Enterprise Value

View Enterprise Value for Perspectum.

Register Today

Perspectum investors also invested in these private companies

Oppenheimer & Co.
Puhua Capital
University of Oxford
BlueCross BlueShield Venture Partners
Oxford Science Enterprises
HealthQuest Capital
Oxford University Innovation


Management Team

Dr. Rajarshi Banerjee
Chief Executive Officer
Amanda Chin
VP Corporate Development
Dr. Keri Hildick
Chief Strategy Officer
Dr. Cat Kelly
Chief Informatics Officer
Debbie Ledet
Chief Access Officer
Dr. Rexford Newbould
Chief Operating Officer
Dr. Matthew Robson
Chief Technical Officer

Board Members

Professor Sir Michael Brady
George Embiricos
Non-Executive Director
Dr. Elizabeth Fagan
Non-Executive Director
Thomas Hawes
Non-Executive Director
Garheng Kong
Kevin Lim
Non-Executive Director
Dr. Michael Rosenblatt
Non-Executive Director
Dr. Emir Sandhu
Non-Executive Director
Chun Tan
Non-Executive Director

Other companies like Perspectum in the Healthcare sector

Last Round Est. Valuation
Last Round Est. Valuation
Last Round Est. Valuation
Last Round Est. Valuation
Last Round Est. Valuation


Perspectum, a precision health company which develops medical imaging tools to improve the diagnoses of metabolic diseases and cancer, has completed the first close of its Series C funding round.